AffyImmune Therapeutics

Executive Summary

AffyImmune Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T cell therapies for solid tumors. Its proprietary platform uses affinity-tuned CAR T cells targeting ICAM-1, which is overexpressed in many cancers, to selectively kill tumor cells while minimizing off-tumor toxicity. The company also developed a noninvasive monitoring system to track CAR T cell persistence and activity in patients. This dual approach addresses key challenges in solid tumor CAR T therapy: target specificity and real-time patient management. AffyImmune's lead candidate, AIC100, is in Phase 1 clinical trials for aggressive forms of thyroid cancer (including anaplastic thyroid carcinoma) and non-small cell lung cancer (NSCLC). Initial data from these studies are expected in the near term, which could provide proof-of-concept for the affinity-tuning strategy and de-risk the platform for broader solid tumor applications. The company is privately held and has not disclosed valuation, but its novel approach and progressing clinical programs position it as an interesting player in the cell therapy space. Key near-term catalysts include initial clinical data readouts and potential expansion into additional indications.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim data for AIC100 in anaplastic thyroid carcinoma70% success
• Q1 2027IND submission for AIC100 in non-small cell lung cancer80% success
• TBDPotential partnership for noninvasive monitoring technology50% success